Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Medtronic starts human study of Endurant graft system

Medtronic starts human study of Endurant graft system

18th December 2007

Medtronic has announced the initiation of the first human study of its Endurant graft system to be used for the treatment of abdominal aortic aneurysm.

The new device aims to develop minimally invasive treatment for patients with challenging anatomies and give doctors an increased range of treatment options, with a lower delivery profile and flexible features used to enhance trackability and conformability in tortuous aneurysmal anatomies.

In total, the study will assess the safety and efficacy of the Endurant system at ten sites located in the Netherlands and Germany, with the results of these trials used to support the application for regulatory approval in Europe.

Katie Szyman, vice-president and general manager of the endovascular innovations business at Medtronic, said: “The Endurant stent graft system underscores our commitment to developing new and better ways to treat abdominal aortic aneurysm with minimally invasive medical technology.”

She added that the trial of this system represents a new platform in its increasing endovascular product portfolio.

In July 2007, Medtronic signed an agreement to purchase Kyphon for a total consideration of $3.9 billion (1.9 billion pounds), the equivalent of $71 per share in cash, a 32 per cent premium over the closing price of the company that month.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.